NuoDB is an SQL database management system that has been designed for distributed deployment in the cloud. NuoDB has the same characteristics of your average SQL databases but it also incorporates features for supporting scale-out processing in environments specifically made for cloud-computing. It’s possible for application programs to communicate with NuoDB through SQL statements and the database has ACID compliance for reliability. NuoDB utilizes a three-tier structure with storage, transactional, and administrative tiers. This tier system means that that NuoDB can work without close coupling and application and its data on a disk drive.
NuoDB was launched by Barry Morris, enterprise software executive, and Jim Starkey, database architect and innovator, in 2010. They had the vision to develop a database that builds on the power of SQL technology to break the traditional database mold that was originally designed over thirty years ago.
NuoDB is made up of a senior management team that includes former executives from seasoned organizations such as Endeca, Hewlett-Packard Enterprise, and StreamBase Systems.
Since NuoDB was founded, it has received its first patent in just 15 months and five other patents are currently pending.
NuoDB’s mission is to deliver better performance, reduce costs, and save more time.
They say that the types of experiences one has when they are growing up shape him for a particular destiny. Well, Doug Levitt had quite an eventful life, especially his teenage and this is probably one of the things that made him so empathetic to the human condition. He grew up in the DC public school system before he joined college. He acceded to the London School of Economics after his undergraduates under a Full Bright Scholarship and studied international relations.
The one event that played the most important role in shaping his destiny was his father committing suicide when Doug was a teenager. His father’s sad demise left a lot of questions in Doug about the human condition. He started his journey in the Greyhound buses ten years ago. His main aim of the project was to meet people from the other side of the society that most people do not like interacting with. The Greyhound buses, for example, are a favorite for people such as prisoners that have been released from the correctional facilities and are trying to make their way back to the society. Doug states that through his interactions with these people, there is a lot that he had learned about the community.
Before he started his journey, Doug Levitt was a very successful foreign correspondent for the international media houses. He worked with CNN and MSNBC on various projects and in locations such as Iraq and other war-torn countries like Rwanda and Kosovo. The job is another opportunity that Levitt got to deal with people that were at their lowest. All these are events that he recorded, and the result was the beautiful album by the name of Greyhound Diaries.
He narrates the story of one of the men that he met in the Greyhound buses. The man had just been released from the system and had all the tattoos to show the situation. He was generous enough to tell him everything he wanted to know about the inside and even let him take the seats as he slept on the floor. Doug clearly has been through enough to understand the human condition entirely.
Seattle Genetics is a biotechnology company that creates and commercializes cutting-edge, empowered antibody-based therapies for treating cancer and other chronic illnesses. The effort to improvise cancer treatment is due to the increased late effects experienced by cancer survivors. The effects range from mild to severe. Other effects such as anemia improve or fade with time while some may be permanent like certain types of nerve damage. In many cases, medical experts cannot always procrastinate if the effects will occur.
Conventional cancer treatments are known for having late effects some cancer patients. Seattle Genetics is the market leader in antibody conjugates (ADCs) and strives to develop advanced cancer treatments. An antibody conjugate is a technology designed to control the targeting capability of monoclonal antibodies to produce cell-killing components. ADCs are aimed at sparing non-targeted cells hence minimizing most toxic effects of traditional chemotherapy, while possibly improving antitumor activity. In addition to the ADCs, the company is coming up with a large product offering to address unmet medical conditions.
Seattle Genetics was established in 1998 and has its corporate headquarters in Bothell, Washington. For almost 20 years, Seattle Genetics has developed designed monoclonal antibodies. The treatment has provided therapeutic benefit to cancer patients, people with autoimmune diseases and other chronic medical conditions. The antibody-based therapies have advanced cancer treatment by targeting malignant cells and preventing damage to normal tissues.
Clay Siegall is the president, co-founder and chief executive officer of Seattle Genetics. He is a scientist by profession and has built Seattle Genetics on a foundation of thorough research, scientific advancement, and drug development practices. Dr. Siegall focuses on targeted cancer therapies due to his passion for helping clients.
Under Dr. Siegall‘s leadership, Seattle Genetics has attained its current leadership position in creating antibody-drug conjugates (ADCs) and the 2011 FDA approval of ADCETRIS® (brentuximab vedotin), the company’s first ADC product. He has also spearheaded the company’s capital-raising initiatives, raising more than $675 million through private and public financing.